Egetis Therapeutics AB (STU:P0F) Cyclically Adjusted FCF per Share: €-0.12 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:P0F Egetis Therapeutics AB STU:P0F
45 GF Score
Price €0.55
GF Value €0.48
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB Cyclically Adjusted FCF per Share?

Egetis Therapeutics AB STU:P0F -0.36% 45 Cyclically Adjusted FCF per Share is €-0.12 as of Mar. 2026. GuruFocus rates STU:P0F with a GF Score™ of 45/100 and a GF Value™ of €0.48 (Modestly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Egetis Therapeutics AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.015. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.12 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 4.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Egetis Therapeutics AB was 9.60% per year. The lowest was -4.30% per year. And the median was 1.10% per year.

As of today (2026-07-21), Egetis Therapeutics AB's current stock price is €0.548. Egetis Therapeutics AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.12. Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF of today is .


Egetis Therapeutics AB  (STU:P0F) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Egetis Therapeutics AB Cyclically Adjusted FCF per Share Related Terms


Egetis Therapeutics AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Egetis Therapeutics AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egetis Therapeutics AB Cyclically Adjusted FCF per Share Chart

Egetis Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.13 -0.14 -0.14 -0.13 -0.12

Egetis Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.12 -0.12 -0.12 -0.12

STU:P0F vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Cyclically Adjusted Price-to-FCF falls into.


STU:P0F
45GF Score
Egetis Therapeutics AB STU:P0F
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egetis Therapeutics AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Egetis Therapeutics AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.015/133.5600*133.5600
=-0.015

Current CPI (Mar. 2026) = 133.5600.

Egetis Therapeutics AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.041 101.019 -0.054
201609 -0.027 101.138 -0.036
201612 -0.026 102.022 -0.034
201703 -0.023 102.022 -0.030
201706 -0.037 102.752 -0.048
201709 -0.019 103.279 -0.025
201712 -0.085 103.793 -0.109
201803 -0.028 103.962 -0.036
201806 -0.049 104.875 -0.062
201809 -0.030 105.679 -0.038
201812 -0.036 105.912 -0.045
201903 0.048 105.886 0.061
201906 -0.046 106.742 -0.058
201909 -0.057 107.214 -0.071
201912 -0.058 107.766 -0.072
202003 -0.058 106.563 -0.073
202006 -0.055 107.498 -0.068
202009 -0.040 107.635 -0.050
202012 -0.021 108.296 -0.026
202103 -0.019 108.360 -0.023
202106 -0.021 108.928 -0.026
202109 -0.017 110.338 -0.021
202112 -0.014 112.486 -0.017
202203 -0.018 114.825 -0.021
202206 -0.017 118.384 -0.019
202209 -0.018 122.296 -0.020
202212 -0.035 126.365 -0.037
202303 -0.029 127.042 -0.030
202306 -0.022 129.407 -0.023
202309 -0.032 130.224 -0.033
202312 -0.013 131.912 -0.013
202403 -0.016 132.205 -0.016
202406 -0.017 132.716 -0.017
202409 -0.019 132.304 -0.019
202412 -0.013 132.987 -0.013
202503 -0.017 132.825 -0.017
202506 -0.015 133.699 -0.015
202509 -0.012 133.480 -0.012
202512 -0.021 133.390 -0.021
202603 -0.015 133.560 -0.015

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.12 mean?
Egetis Therapeutics AB (STU:P0F) has a Cyclically Adjusted FCF per Share of €-0.12 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Egetis Therapeutics AB and its competitors.
Is Egetis Therapeutics AB's Cyclically Adjusted FCF per Share too high?
Egetis Therapeutics AB's current Cyclically Adjusted FCF per Share is €-0.12. Overall, Egetis Therapeutics AB has a GF Score™ of 45/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Egetis Therapeutics AB's Cyclically Adjusted FCF per Share of €-0.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Egetis Therapeutics AB and its competitors. Egetis Therapeutics AB's current Cyclically Adjusted FCF per Share is €-0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (STU:P0F) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.48, compared to a current price of €0.55 — trading 14.2% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.12. Egetis Therapeutics AB's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Egetis Therapeutics AB (STU:P0F), the current Cyclically Adjusted FCF per Share is €-0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egetis Therapeutics AB (STU:P0F) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued. The current stock price of €0.55 is trading 14.2% above its estimated GF Value™ of €0.48. GuruFocus considers Egetis Therapeutics AB to be Modestly Overvalued.

Key valuation signals for STU:P0F:

  • Cyclically Adjusted FCF per Share: €-0.12
  • GF Value™: €0.48 vs. price of €0.55 (14.2% above fair value)
  • GF Score™: 45/100 with 7 warning signs

No single metric tells the full story. See the STU:P0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Egetis Therapeutics AB Business Description

Other Exchanges PDPHF:USAEGTX:Sweden0ABW:UK
Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
45GF Score

Get the complete analysis for STU:P0F

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.55
Price
€0.48
GF Value